Cite

HARVARD Citation

    Dakin, H. et al. (2014). Cost-effectiveness of ranibizumab and bevacizumab for age-related macular degeneration: 2-year findings from the IVAN randomised trial. BMJ open. 4 (7), p. . [Online]. 
  
Back to record